|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
2/21/2013
|
BERTHELSEN SPENCER R
|
Director
|
10,000
|
$5.17
|
34.13%
|
|
2/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
1,600
|
$10.29
|
120.85%
|
|
2/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-1,600
|
$14.80
|
-54.72%
|
|
2/15/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-250
|
$14.82
|
-15.88%
|
|
2/15/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-100
|
$14.80
|
-7.02%
|
|
2/15/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
250
|
$10.29
|
18.88%
|
|
2/15/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
100
|
$10.29
|
7.55%
|
|
2/13/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-139
|
$14.17
|
-9.50%
|
|
2/13/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-5,200
|
$14.17
|
-78.04%
|
|
2/13/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
5,200
|
$7.25
|
355.43%
|
|
2/13/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-900
|
$14.17
|
-38.09%
|
|
2/13/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
900
|
$8.00
|
61.52%
|
|
1/30/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
-2,000
|
$14.82
|
-57.75%
|
|
1/30/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
2,000
|
$10.29
|
136.71%
|
|
1/29/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
-300
|
$13.40
|
-17.02%
|
|
1/17/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-242
|
$14.16
|
-12.07%
|
|
1/16/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
-759
|
$14.00
|
-20.51%
|
|
1/16/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
-242
|
$14.00
|
-44.65%
|
|
1/16/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
-95
|
$14.00
|
-1.64%
|
|
1/16/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
-235
|
$14.00
|
-4.04%
|
|
1/16/2013
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-143
|
$14.00
|
-45.11%
|
|
1/16/2013
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-1,317
|
$14.00
|
-44.22%
|
|
1/16/2013
|
Geary Richard S
|
SVP, Development
|
-345
|
$14.00
|
-7.50%
|
|
1/16/2013
|
BENNETT C FRANK
|
SVP, Antisense Research
|
-309
|
$14.00
|
-12.77%
|
|
1/4/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
-1,296
|
$10.76
|
-46.97%
|
|
1/3/2013
|
Geary Richard S
|
Sr VP, Development
|
-265
|
$10.84
|
-6.48%
|
|
1/3/2013
|
Monia Brett P
|
VP, Antisense Drug Discovery
|
-311
|
$10.84
|
-5.55%
|
|
1/1/2013
|
Geary Richard S
|
Sr VP, Development
|
898
|
$8.87
|
28.15%
|
|
1/1/2013
|
BENNETT C FRANK
|
SVP, Antisense Research
|
447
|
$8.87
|
35.00%
|
|
1/1/2013
|
Monia Brett P
|
VP, Antisense Drug Discovery
|
215
|
$8.87
|
3.99%
|
|
1/1/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
431
|
$8.87
|
18.51%
|
|
12/13/2012
|
Geary Richard S
|
Sr VP, Development
|
6,000
|
$5.25
|
188.09%
|
|
12/13/2012
|
Geary Richard S
|
Sr VP, Development
|
-6,000
|
$9.63
|
-65.29%
|
|
9/21/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-29,462
|
$14.06
|
-100.00%
|
|
9/20/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-9,462
|
$15.01
|
-100.00%
|
|
9/20/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
20,538
|
$15.01
|
100.00%
|
|
9/19/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-30,000
|
$14.82
|
-100.00%
|
|
9/13/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-27,074
|
$14.55
|
-100.00%
|
|
9/7/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
-5,000
|
$15.12
|
-100.00%
|
|
9/7/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
-2,506
|
$15.12
|
-55.80%
|
|
9/7/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
2,506
|
$6.84
|
126.25%
|
|
9/6/2012
|
Monia Brett P
|
VP, Antisense Drug Discovery
|
-12,031
|
$15.25
|
-69.08%
|
|
9/6/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-4,381
|
$15.04
|
-100.00%
|
|
9/6/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-1,925
|
$15.04
|
-100.00%
|
|
9/6/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-8,694
|
$15.04
|
-100.00%
|
|
9/6/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-306
|
$15.00
|
-100.00%
|
|
9/6/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-6,000
|
$15.00
|
-100.00%
|
|
9/6/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-8,694
|
$15.00
|
-100.00%
|
|
9/6/2012
|
Monia Brett P
|
VP, Antisense Drug Discovery
|
12,031
|
$5.25
|
223.46%
|
|
9/6/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
-5,000
|
$15.04
|
-100.00%
|
|
9/6/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
2,494
|
$6.84
|
125.64%
|
|
9/6/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
-2,494
|
$15.04
|
-55.68%
|
|
9/6/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
2,506
|
$5.25
|
126.25%
|
|
9/6/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
-2,506
|
$15.04
|
-55.80%
|
|
9/6/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
-5,000
|
$15.00
|
-100.00%
|
|
9/6/2012
|
REED JOHN C
|
Director
|
-4,900
|
$15.18
|
-100.00%
|
|
9/5/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
2,000
|
$5.25
|
100.76%
|
|
9/5/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
-2,000
|
$15.00
|
-50.19%
|
|
9/5/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-15,000
|
$14.82
|
-100.00%
|
|
9/4/2012
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-30,000
|
$14.11
|
-100.00%
|
|
9/4/2012
|
REED JOHN C
|
Director
|
-5,100
|
$15.17
|
-100.00%
|
|
9/4/2012
|
PARSHALL B LYNNE
|
COO, Secretary
|
-10,000
|
$15.00
|
-100.00%
|
|
7/9/2012
|
REED JOHN C
|
Director
|
-10,000
|
$13.99
|
-100.00%
|
|
7/9/2012
|
Geary Richard S
|
Sr VP, Development
|
-1,000
|
$13.45
|
-23.87%
|
|
7/9/2012
|
Geary Richard S
|
Sr VP, Development
|
1,000
|
$5.25
|
31.35%
|
|
7/9/2012
|
Geary Richard S
|
Sr VP, Development
|
-2,000
|
$13.49
|
-38.54%
|
|
7/9/2012
|
Geary Richard S
|
Sr VP, Development
|
-2,686
|
$13.47
|
-45.71%
|
|
7/9/2012
|
Geary Richard S
|
Sr VP, Development
|
2,000
|
$5.25
|
62.70%
|
|
7/9/2012
|
Geary Richard S
|
Sr VP, Development
|
2,686
|
$5.25
|
84.20%
|
|
7/9/2012
|
BENNETT C FRANK
|
SVP, Antisense Research
|
-5,000
|
$13.51
|
-79.66%
|
|
7/9/2012
|
BENNETT C FRANK
|
SVP, Antisense Research
|
5,000
|
$6.81
|
391.54%
|
|
7/9/2012
|
BENNETT C FRANK
|
SVP, Antisense Research
|
-5,500
|
$13.51
|
-81.16%
|
|
7/9/2012
|
BENNETT C FRANK
|
SVP, Antisense Research
|
5,500
|
$6.84
|
430.70%
|
|
7/3/2012
|
Geary Richard S
|
Sr VP, Development
|
-2,434
|
$12.91
|
-43.28%
|
|
7/3/2012
|
BENNETT C FRANK
|
SVP, Antisense Research
|
-6,000
|
$12.91
|
-82.45%
|
|
7/3/2012
|
BENNETT C FRANK
|
SVP, Antisense Research
|
6,000
|
$6.84
|
469.85%
|
|
7/3/2012
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
-587
|
$12.92
|
-9.83%
|
|
7/1/2012
|
Geary Richard S
|
Sr VP, Development
|
1,300
|
$6.13
|
30.06%
|
|
7/1/2012
|
BENNETT C FRANK
|
SVP, Antisense Research
|
648
|
$6.13
|
103.02%
|
|
7/1/2012
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
311
|
$6.13
|
5.49%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
700
|
$8.15
|
2.39%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-700
|
$11.56
|
-2.33%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
3,500
|
$8.15
|
11.95%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-3,500
|
$11.58
|
-10.67%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
1,500
|
$8.15
|
5.12%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-1,500
|
$11.58
|
-4.87%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
100
|
$8.15
|
0.34%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-100
|
$11.59
|
-0.34%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
1,600
|
$8.15
|
5.46%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
172
|
$8.15
|
0.59%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-172
|
$11.62
|
-0.58%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-1,600
|
$11.60
|
-5.18%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-495
|
$11.55
|
-1.66%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
495
|
$8.15
|
1.69%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-300
|
$11.48
|
-1.01%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
200
|
$8.15
|
0.68%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
300
|
$8.15
|
1.02%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-200
|
$11.49
|
-0.68%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-300
|
$11.49
|
-1.01%
|
|
6/25/2012
|
BERTHELSEN SPENCER R
|
Director
|
-200
|
$11.50
|
-0.68%
|